Journal article
Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in relapsed multiple myeloma patients with renal impairment: IKEMA subgroup analysis
Haematologica, Vol.107, pp.1397-1409
2021
Abstract
Renal impairment (RI) is common in patients with multiple myeloma (MM) and new therapies that can improve renal function are needed. The phase III IKEMA study (clinicaltrials gov. Identifier: NCT03275285) investigated isatuximab (Isa) with carfilzomib and dexamethasone (Kd) versus Kd in relapsed MM. This subgroup analysis examined results from patients with RI, defined as estimated glomerular filtration rate <60 mL/min/1.73 m². Addition of Isa prolonged progression-free survival (PFS) in patients with RI (hazard ratio: 0.27; 95% confidence interval [CI]: 0.11–0.66; median PFS not reached for Isa-Kd versus 13.4 months for Kd [20.8-month follow-up]). Complete renal responses occurred more frequently with Isa-Kd (52.0%) versus Kd (30.8%) and were durable in 32.0% versus 7.7% of patients, respectively. Treatment exposure was longer with Isa-Kd, with median number of started cycles and median duration of exposure of 20 versus 9 cycles and 81.0 versus 35.7 weeks for Isa-Kd versus Kd, respectively. Among patients with RI, the incidence of patients with grade ≥3 treatment-emergent adverse events was similar between the two arms (79.1% in Isa-Kd vs. 77.8% in Kd). In summary, the addition of Isa to Kd improved clinical outcomes with a manageable safety profile in patients with RI, consistent with the benefit observed in the overall IKEMA study population.
Details
- Title
- Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in relapsed multiple myeloma patients with renal impairment: IKEMA subgroup analysis
- Authors/Creators
- M. Capra (Author/Creator)T. Martin (Author/Creator)P. Moreau (Author/Creator)R. Baker (Author/Creator)L. Pour (Author/Creator)C-K Min (Author/Creator)X. Leleu (Author/Creator)M. Mohty (Author/Creator)M.R. Segura (Author/Creator)M. Turgut (Author/Creator)R. LeBlanc (Author/Creator)M-L Risse (Author/Creator)L. Malinge (Author/Creator)S. Schwab (Author/Creator)M. Dimopoulos (Author/Creator)
- Publication Details
- Haematologica, Vol.107, pp.1397-1409
- Publisher
- Ferrata Storti Foundation
- Identifiers
- 991005540654207891
- Copyright
- © 2022 by the Ferrata Storti Foundation
- Murdoch Affiliation
- Murdoch University
- Language
- English
- Resource Type
- Journal article
UN Sustainable Development Goals (SDGs)
This output has contributed to the advancement of the following goals:
Source: InCites
Metrics
23 File views/ downloads
41 Record Views
InCites Highlights
These are selected metrics from InCites Benchmarking & Analytics tool, related to this output
- Collaboration types
- Industry collaboration
- Domestic collaboration
- International collaboration
- Citation topics
- 1 Clinical & Life Sciences
- 1.130 Lymphomas
- 1.130.617 Multiple Myeloma
- Web Of Science research areas
- Hematology
- ESI research areas
- Clinical Medicine